FindTrial
Sign In

Reduced Intensity Conditioning

DRUG8 trials

Sponsors

University of Michigan Rogel Cancer Center, Hospices Civils de Lyon, Duke University, European Society for Blood and Marrow Transplantation, New York Medical College

Conditions

Autoimmune LymphoproliferativeCommon Variable ImmunodeficiencyCongenital Marrow FailuresHemoglobinopathiesHodgkin LymphomaImmune System DiseasesImmunodeficienciesInborn Errors of Metabolism

Phase 1

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
CompletedNCT00744692
Duke UniversityCongenital Marrow Failures, Hemoglobinopathies, Immunodeficiencies +5
Start: 2008-10-31End: 2014-04-30Updated: 2014-08-13
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
NCT02098512
New York Medical CollegeHodgkin Lymphoma
Start: 2014-03-01End: 2022-12-31Target: 20Updated: 2022-10-27

Phase 2

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
CompletedNCT00143845
University of Michigan Rogel Cancer CenterLymphocytic Leukemia, Chronic, Lymphoma, Low-Grade, Multiple Myeloma
Start: 2003-04-30End: 2013-02-28Updated: 2017-03-08
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
TerminatedNCT00143884
University of Michigan Rogel Cancer CenterLeukemia, Lymphoma, Low-Grade, Lymphoma, Non-Hodgkin's +2
Start: 2000-03-31Target: 30Updated: 2007-04-23
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning
CompletedNCT00466674
Hospices Civils de LyonMyeloma
Start: 2007-01-31End: 2013-09-30Updated: 2025-12-19
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RecruitingNCT02579967
National Cancer Institute (NCI)Autoimmune Lymphoproliferative, Common Variable Immunodeficiency, Immune System Diseases +2
Start: 2015-11-19End: 2036-12-31Target: 354Updated: 2026-03-27
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Active, not recruitingNCT03663933
National Cancer Institute (NCI)Autoimmune Lymphoproliferative, Common Variable Immunodeficiency, Immune System Diseases +2
Start: 2018-09-04End: 2030-04-03Updated: 2026-03-17

Phase 3

Dose-reduced Versus Standard Conditioning in MDS/sAML
TerminatedNCT01203228
European Society for Blood and Marrow TransplantationMyelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Start: 2004-05-31End: 2015-02-28Updated: 2015-04-03

Related Papers

BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients with Primary Immunodeficiency
Biology of Blood and Marrow Transplantation2020-01-23
Safety and Efficacy of Donor Leukocyte Infusion for Single Unit Umbilical Cord Blood Transplantation to Accelerate Immune Reconstitution Prior to Thymopoiesis
Biology of Blood and Marrow Transplantation2019-01-31
Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)
Blood2018-11-294 citations
Donor Leukocyte Infusion for Single Unit Umbilical Cord Blood Transplantation: 5% of Thawed Single Cord Blood Unit Refrozen on Day of Transplant Is Safe with Signals of Efficacy in Improving Donor Derived Immunity
Blood2018-11-29
A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.
2013-12-0136 citations